Background Despite widespread use of intrapartum antibiotic prophylaxis, group B streptococcus remains a leading cause of morbidity and mortality in infants in Europe, the Americas, and Australia. However, estimates of disease burden in many countries outside of these regions is not available. We aimed to examine the current global burden of invasive disease and the serotype distribution of group B streptococcus isolates.
Introduction
Group B streptococcus (Streptococcus agalactiae) is the most common cause of neonatal sepsis in high-income countries.
1,2 Disease risk is highest during the fi rst 3 months of life and declines substantially thereafter. Earlyonset disease (day 0-6) is the result of vertical transmission from a colonised mother during or just before delivery. 3 Late-onset disease (day 7-89) can be acquired from the mother or from environmental sources. 4, 5 Case fatality from both early-onset and late-onset disease is high, even with antibiotic therapy. 2, 3 Group B streptococcus is also an important cause of preterm delivery, antepartum and intrapartum stillbirth, and puerperal sepsis. 6, 7 Prevention of early-onset group B streptococcus has become a realistic option, through the use of intrapartum antibiotics given to pregnant women with risk factors or known carriage of the bacteria (intrapartum antibiotic prophylaxis). [8] [9] [10] This prophylaxis has been implemented in most high-income countries since the late 1990s, but has been diffi cult to implement in many low-income countries and middle-income countries. [11] [12] [13] Several group B strepto coccus vaccines are also at various stages of testing and could allow prevention of both early-onset disease and late-onset disease. 6, 14 However, many challenges exist to obtaining accurate estimates of disease burden, especially for low-income and middleincome countries, including diffi culties with obtaining speci mens and poor laboratory capacity for diagnosis of group B streptococcus. We aimed to estimate the incidence of group B streptococcal invasive disease and case fatality in infants aged 0-89 days in the era of intrapartum prophylaxis, estimate the incidence of early and late onset invasive disease, and estimate distribution of group B strepto coccal serotypes in invasive disease specimens. Secondary objectives were to assess how the incidence of group B streptococcus varies with gross national income (GNI) per head and geographical region.
Methods

Defi nitions and classifi cation
We defi ned invasive group B streptococcal disease as laboratory isolation of Streptococcus agalactiae from a normally sterile site in an infant aged 0-89 days with any signs of clinical disease (eg, sepsis, pneumonia, or meningitis).
Search strategy and selection criteria
We searched Medline, Embase, and Wholis databases using the search terms ("Streptococcus agalactiae" [Mesh] OR "Streptococcus Group B" OR "Group B Streptococcal") AND Limits: Humans, Publication date 2000/01/01-2011/09/01. We restricted our search from January 2000, to maintain consistency and comparability with other publications from WHO Global Burden of Disease and the Child Health Epidemiology Reference Group aimed at producing disease burden estimates for 2000. 15 , 16 To ensure we included all studies in which group B streptococcus was not isolated and incidence was zero we reviewed all reports that described incidence or case fatality from the concurrent neonatal infection search in the 2010 global burden of disease project. 16 We also reviewed reference lists and contacted experts to seek unpublished data and data missed by our search. No language restrictions were used.
Reports were excluded if they did not describe data collected between Jan 1, 2000, and Sept 1, 2011, human infants aged 0-89 days at onset of infection episode, specimens obtained from a sterile site, laboratory investigation for common bacterial pathogens such as group B streptococcus, original data (ie, reviews or repeated datasets were excluded), denominator data (eg, case series were excluded); and data representative of the whole population of infants (eg, studies containing only information on very high-risk groups [eg, preterm infants] were excluded).
Only 19 articles with data on serotypes of group B streptococcus fulfi lled the inclusion criteria for the search from Jan 1, 2000 to Sept 1, 2011, thus an additional search for reports with serotype data from Jan 1, 1980, to Sept 1, 2011 was done with the same search strategy outlined above.
Data extraction
Two reviewers (CK, KME) examined titles, abstracts, and articles independently with identical case defi nitions, data abstraction forms, and selection criteria. Dis agreements were resolved by consensus between the two reviewers and the lead authors (CK, KME, PTH).
We gathered basic data on author, country and group B streptococcal cases, deaths, and serotypes ascertained for three age groups: 0-89 days, 0-6 days, and 7-89 days. We also gathered data on livebirths in the study population. If a study only included inborn babies (babies born in the study hospital) then the number of livebirths for the whole hospital was used as denominator data. If a study included outborn babies (babies who were not born in the study hospital but born at home or another health facility) then the number of livebirths in the whole study population (including community births) was used.
We also gathered data on potential explanatory variables (ie, variables that might explain variance in incidence or risk of group B streptococcus; 21 Andersen et al 22 Ekelund et al 23 Kuhn et al 24 Fluegge et al 25 Berardi et al 26 Trijbels-Smeulders et al 27 van den Hoogen et al 28 Hasseltvedt et al 29 Hajdu et al 30 Neto et al 31 Janek et al 32 Carbonell-Estrany et al 33 Lopez Sastre et al 34 Andreu et al 35 Persson et al 36 Heath et al 37 Oddie et al 38 Weisner et al 39 Vergnano et al 40 Subtotal (I 2 =98·6%, p=0·000)
The Americas Martin et al 41 Vaciloto et al 42 Bell et al 43 Trotman et al 44 Castrodale et al 45 Chen et al 46 Hyde et al 47 Mayor-Lynn et al 48 Phares et al 49 Puopolo et al 50 CDC et al 51 Stoll et al 52 CDC et al 53 Brooks et al 54 Cordero et al 55 Jordan et al 56 Subtotal (I 2 =97·4%, p=0·000)
Africa
Berkley et al 57 Gray et al 58 Ojukwu et al 59 Cutland et al 60 Subtotal (I 2 =82·9%, p=0·001)
Eastern Mediterranean
Al-Zwaini et al 61 Tiskumara et al 62 El-Said et al 63 Ben Hamida et al 64 Subtotal (I 2 =65·6%, p=0·033)
Western Pacific Angstetra et al 65 Daley et al 66 May et al 67 Tiskumara et al 62 Tiskumara et al 62 Kim et al 68 Niduvaje et al 69 Subtotal (I 2 =54·7%, p=0·039)
Southeast Asia
Darmstadt et al 70 Sundaram et al 71 Tiskumara et al 62 Tiskumara et al 62 Yossuck 
0·08 (0·00 to 0·43) 0·31 (0·17 to 0·52) 0·50 (0·14 to 1·28) 0·98 (0·49 to 1·76) 0·35 (0·07 to 0·62) 0·00 (0·00 to 0·44) 0·27 (0·10 to 0·58) 0·03 (0·00 to 0·19) 0·31 (0·04 to 1·13) 0·37 (0·21 to 0·59) 0·13 (0·05 to 0·28) 0·22 (0·01 to 1·20) 0·15 (0·04 to 0·27) 0·10 (0·00 to 0·55) 0·00 (0·00 to 0·11) 0·00 (0·00 to 0·79) 0·14 (0·03 to 0·41) 0·09 (0·00 to 0·51) 0·02 (-0·03 to 0·07) 0·53 (0·44 to 0·62) high-middle income, high income), and high versus low (≥70% vs <70%) skilled attendance at birth according to WHO criteria. 15 We categorised studies as prospective (data gathered while the infant was still unwell or in hospital) versus retrospective (data gathered after the infant had been discharged from hospital). Data on site of delivery were also gathered because inborn babies have diff erent risk factors for infection than do babies who are outborn. Also, delay in specimen collection from outborn babies can be longer than in inborn babies. The reporting period was categorised as complete versus incomplete. For example, we looked for data on early-onset incidence over the whole period from day 0-6. If data for this period was available it was classifi ed as complete. However, if information was only available for day 0-2 then data were still recorded but classifi ed as incomplete. Data on specimen type were grouped as specimens from all sterile sites (blood, cerebrospinal fl uid, bone and joint specimens) versus blood only. 18, 19 Only limited information was available for intrapartum antibiotic prophylaxis and studies could only be categorised into use of any intrapartum antibiotic prophylaxis versus no use of intrapartum antibiotic prophylaxis. Infants with low birthweight should comprise 20-30% of all infants with group B streptococcus, 20 thus we also divided studies into three categories of low birthweight: 20% or less, 20-39%, 40% or more.
Group B streptococcal disease is rapidly progressive and under-ascertainment can result if specimens are not obtained within 24 h of disease onset. Thus, we examined articles for indicators such as proportion of specimens collected during the fi rst day of illness or on the day of birth or careseeking and referral on day one of life, but no data were available. Poor laboratory techniques can also cause under-ascertainment of group B streptococcus, so we also searched for information on specimen volume, transport conditions, and culture techniques; but data were disparate and could not be pooled. We also looked for data on HIV status but this was not available in most articles or could not be synthesised.
Year Europe
Strakova et al 21 Fluegge et al 25 Berardi et al 26 Trijbels-Smeulders et al 27 Hasseltvedt et al 29 Hajdu et al 30 Neto et al 31 Carbonell-Estrany et al 33 Persson et al 36 Heath et al 37 Oddie et al 38 Weisner et al 39 Subtotal (I 2 =87·8%, p=0·000)
The Americas Trotman et al 44 Castrodale et al 45 Hyde et al 47 Mayor-Lynn et al 48 Phares et al 49 Puopolo et al 50 Brooks et al 54 Cordero et al 55 Jordan et al 56 Subtotal (I 2 =86·7%, p=0·000) Africa Gray et al 58 Milledge et al 73 Sigauque et al 74 Subtotal (I 2 =59·9%, p=0·083) Western Pacific Matsubara et al 75 Park et al 96 Cho et al 77 Chang et al 78 
0·10 (0·07-0·12)
Group-B-streptococcal death ratio 
Statistical analyses
We used random-eff ects meta-analysis to calculate weighted mean estimates across studies and 95% CIs for incidence of group B streptococcus, case fatality, and serotype distribution. Random-eff ects logistic regression was used to investigate the eff ect of gross national income, WHO region, and other explanatory variables for group B streptococcus estimates while taking account of within-study and within-country correlations. We decided a priori that all eff ect measures should be adjusted for study design, delivery site, reporting period, specimen type, intrapartum antibiotic use, and proportion of low birthweight infants in the fi nal model. However, we judged that gross national income, WHO region, and skilled attendance would be highly correlated and only gross national income should be included in the fi nal model. Crude and adjusted odds ratios and their 95% CIs were calculated. Statistical analyses were done with STATA (version 11).
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication. To assess whether any publication bias was likely in our study we did scatter plots of incidence and case fatality rate against sample size and SE to determine whether any correlation existed. These analyses yielded non-signifi cant results both for data on incidence (p=0·223) and case fatality (p=0·206).
Results
56 papers reported incidence data for the overall period 0-89 days (table 1) . Studies from low-income countries carried only 5% weight in the meta-analysis. Mean incidence was 0·53 per 1000 livebirths (95% CI 0·44-0·62; fi gure 1). Incidence was highest in Africa followed by the Americas and Europe. Southeast Asia had the lowest incidence. The studies were very heterogeneous in both the overall analysis and within regions (p<0·0001), except for southeast Asia (p=0·612). Even within countries a great deal of heterogeneity existed.
42 studies reported incidence data for early-onset (0-6 days) group B streptococcus; 31 (74%) had data for the complete period (0-6 days) and 34 (81%) reported use of intrapartum antibiotic prophylaxis. Only three lowincome countries (Kenya, Malawi, Bangladesh) had data for early-onset group B streptococcus. The mean 
Groups (%)
A m e r i c a s n = 9 A f r i c a n = 2 A s i a n = 0 E u r o p e n = 1 9 M e d i t e r r a n e a n n = 1 P a c i fi c n = 7 E a r ly -o n s e t d i s e a s e n = 1 2 See Online for webappendix incidence of early-onset disease was 0·43 (95% CI 0·37-0·49). Incidence was highest in studies from Africa (0·53, 95% CI 0·15-0·92]) followed by the Americas (0·50, 0·43-0·57) and Europe (0·45, 0·34-0·56). Studies from southeast Asia reported the lowest incidence (0·11, 95% CI 0·012-0·220). 18 papers reported any data for incidence of late-onset (7-89 days) group B streptococcus. The average incidence of late-onset disease was 0·24 (95% CI 0·17-0·30). Incidence was again highest in Africa (0·71, 95% CI 0·38-1·04) followed by the Americas (0·31, 0·16-0·89).
L a t e -o n s e t d i s e a s
29 papers reported data for case fatality in infants aged 0-89 days; 484 deaths occurred in 6135 infants positive for group B streptococcus (table 1). The mean case fatality ratio was 9·6% (95% CI 7·5-11·8; fi gure 2). Early-onset case fatality (12·1%, 95% CI 6·2-18·3) was twice as high as late-onset death (6·8%, 4·3-9·4). The case fatality ratio was three times higher in low-income countries (12·6%, 95% CI 10·8-14·9) than in high-income countries (4·6%, 2·1-9·1). 
Data are number or incidence (95% CI), odds ratio (95% CI), or adjusted odds ratio (95% CI). *Proportion of infants with group B streptococcus who were low birthweight. †Adjusted for gross national income, design, delivery site, reporting period, specimen type, use of intrapartum antibiotic prophylaxis, and proportion of infants with low birthweight. 38 serotype studies published from Jan 1, 1980 to June 1, 2011, fulfi lled the inclusion criteria (table 1, fi gure 3). Serotype III accounted for almost half of all isolates followed by serotypes Ia, Ib, II, and V; a small proportion of serotypes were non-typeable (fi gure 3).
No serotype studies from southeast Asia were identifi ed, and only one study from the eastern Mediterranean region (Morocco) and two studies from Africa (Nigeria and South Africa) were recorded. Distribution of group B streptococcus serotypes seemed to be similar across WHO regions (fi gure 3 33 serotype studies were from high-income countries. Five studies from middle-income countries (South Africa, Nigeria, Morocco, Romania, and Argentina) reported serotypes; 94 (43%) of 221 cases in middle-income countries were serotype III. However, no serotype studies from lowincome countries were identifi ed.
We also examined serotype distribution by disease onset (fi gure 3). 221 (37%) of 604 early-onset serotypes were type III by contrast with 347 (53%) of 653 late-onset serotypes. 242 (40%) early-onset serotypes were type I compared with 196 (30%) of late-onset serotypes. By contrast, serotype distribution did not seem to change substantially over the three decades of data collection. Serotype III accounted for 48% (1324) of isolates in the 1980s, 49% (822) of isolates in the 1990s, and 50% (544) of the isolates from 2000-10. Serotype V accounted for 9% (245) of isolates in the 1980s, 9% (143) of isolates in the 1990s, and 10% (112) of the isolates from 2000-10.
The only explanatory variables that seemed to be strongly predictive of group B streptococcus risk were the proportion of infants positive for group B streptococcus who had low birthweight and reporting period (table 2) . Studies with less than 20% of infants with low birth weight reported lower odds of group B streptococcal infection than did studies with proportions ranging from 20-39%. Studies with incomplete reporting recorded lower odds of group B streptococcal infection than did studies with complete reporting.
Infants in countries with low gross national income had higher odds of group B streptococcal infection than did those in countries with high gross national income, but this result was not signifi cant (table 2) . No association was reported between incidence of group B streptococcus and gross national income (adjusted odds ratio 0·99, 95% CI 0·97-1·01, p=0·071). Incidence of group B streptococcus in infants aged 0-89 days was higher in studies that reported no use of intrapartum antibiotic prophylaxis than in infants in studies that reported any intrapartum antibiotic prophylaxis, but this eff ect was not signifi cant (table 2) .
We also constructed a multivariable model to closely investigate the eff ect of WHO region. In this analysis only the Asian region had a signifi cantly diff erent risk of group B streptococcus than the baseline group (Americas; adjusted odds ratio 0·077, 95% CI 0·023-0·260) after adjusting for all variables in the initial model except for gross national income.
We also repeated the analyses, assessing the eff ect of all explanatory variables on early-onset incidence of group B streptococcus. The only variable with an important association with risk of early-onset disease was use of intrapartum antibiotic prophylaxis. No use of prophylaxis was associated with a 2·2 times increased odds of early-onset group B streptococcal infection (odds ratio 2·20, 95% CI 1·59-3·40; incidence of early-onset disease 0·23 per 1000 livebirths in studies with any intrapartum antibiotic prophylaxis com pared with 0·75 per 1000 livebirths in studies with no intrapartum antibiotic prophylaxis).
Discussion
More studies are needed to accurately estimate the global burden of group B streptococcus, especially in low-income countries. We judge our overall estimate of group B streptococcus incidence (0·53 per 1000 livebirths) to be an underestimate of the global incidence. Incidence and case fatality were two-times higher in infants who had group B streptococcal disease in the fi rst week of life (0-6 days) compared with later infancy (7-89 days). The disease is often rapidly fulminating and many cases can be missed because of diffi culties with obtaining specimens before babies die. This issue is especially important in African and Asian countries with high case-fatality rates due to group B streptococcus. Our estimate also mirrors the current use of intrapartum antibiotic prophylaxis in high-income countries as it was used in almost 70% of the studies. This intervention has high effi cacy in preventing early-onset group B streptococcus and has substantially reduced the incidence of early-onset disease since its introduction in the 1990s. 8, 9, 37 Risk of group B streptococcal disease was two-times less in studies with small proportions (<20%) of infected low-birthweight infants than in studies with proportions ranging from 20-39%. Infants with low birthweight have a high risk of group B streptococcal infection and underrepresentation in a study sample can lead to substantial underestimations. 37 Studies done in the UK and USA report an eight-times greater risk of group B streptococcal infection in infants under 1·5 kg and up to three-times greater risk in infants 1·4-2·5 kg than babies with normal birthweight. 37, 47 Studies done in Africa reported the highest incidence of group B streptococcal disease; almost three-times higher than in the Americas. By contrast, studies done in southeast Asia reported the lowest risk and two studies in this region reported no group B streptococcus. The disparities between Africa and Asia are striking. The low incidence in Asia could be a true regional estimate or could be due to high previous antibiotic use, high case fatality before specimen collection, or study design issues including small sample sizes and incomplete periods for data collection.
Distribution of group B streptococcus serotypes was strikingly similar across the WHO regions and no evidence was shown that distribution had changed over the past 30 years. Serotype III accounted for almost half of all the isolates followed by serotype Ia, II, and V. Five studies from middle-income countries (South Africa, Nigeria, Morocco, Romania, and Argentina) reported on distribution of serotypes. However, no studies in southeast Asia and in low-income countries were identifi ed and serotypes might be diff erent in these countries.
Our review had some limitations. Infants born to HIV-positive mothers have a high risk of late-onset group B streptococcal disease, 80 but we were unable to assess the eff ect of HIV status in our meta-analysis due to insuffi cient data. We also were only able to include fi ve studies from low-income countries and fi ve studies from Asia and calculation of representative estimates of global or regional incidence of group B streptococcus were not possible. We also had few indicators of study quality. We were not able to obtain data on the proportion of specimens taken within 24 h of disease onset and had no clear measures of laboratory accuracy and reliability.
We also did not provide estimates of group B streptococcal cases and deaths by WHO region because we judged the studies to be too heterogeneous. This heterogeneity was due to the wide range of data sources retained, especially in the studies from low-income countries. However, we did adjust our regression analyses for important explanatory variables and presented both unadjusted and adjusted eff ect measures. Also, an important strength of our study was our comprehensive search strategy. We included all papers from the concurrent global burden of disease neonatal infection study regardless of whether group B streptococcus was isolated or not. Our study also seems to be the fi rst synthesis of global group B streptococcus incidence, case fatality, and serotype data. Previous Cochrane reviews have only assessed the eff ect of important preventive interventions such as intrapartum antibiotic prophyl axis 81, 82 and vaginal chlorhexidine. 83 We included both inborn and outborn babies but all studies had to include contact with a hospital that could undertake laboratory investigations for common bacterial pathogens such as group B streptococcus. These studies are biased towards patients with severe disease, 84, 85 and more babies with group B streptococcal infection could have been included in these studies than those in the total population, thereby infl ating our incidence estimate. Families who attend hospitals also have better access to health care and higher socioeconomic status than do those who do not attend hospitals. 86 However, we showed that studies with lowest levels of skilled attendance at delivery (<70%) and lowest gross national income reported the highest risk of group B streptococcal infection. This fi nding contrasts with other studies that suggest that mothers with the highest socioeconomic status have the highest risk of infection. 87, 88 This study has important implications for research and policy development. Low-income countries had the highest risk of group B streptococcus disease and mortality, yet little incidence and serotype data were available from these countries. High-quality group B streptococcus data are urgently needed from low-income countries, especially from Asia. These data are required to formulate prevention policies including the optimum use of intrapartum antibiotic prophylaxis and the potential use of group B streptococcus vaccines.
A simple risk-based algorithm for use of intrapartum antibiotic prophylaxis in preterm deliveries, premature rupture of membranes, and maternal pyrexia could be applied in health facilities in low-income countries. However, because of logistical issues, very few lowincome countries are implementing any intrapartum antibiotic policies despite their known effi cacy; and even when policies are implemented, they are often limited. Intrapartum antibiotic prophylaxis also is not currently reaching the women most in need-those with high-risk home deliveries. 8, 89 Emphasis must be placed on improving use of intrapartum antibiotic prophylaxis in low-income settings.
Our data also indicate that a conjugate vaccine incorporating fi ve serotypes (Ia, Ib, II, III, V) could prevent over 85% of global group B streptococcal disease in infants aged younger than 3 months. Serotype distribution seems to be similar in Africa, western Pacifi c, Europe, the Americas, and the eastern Mediterranean regions and has not changed over the past 30 years. This fi nding contrasts with the regional variation in serotype distribution seen with other vaccine preventable diseases. 90, 91 Group B streptococcus conjugate vaccines are at advanced stages of testing and phase 3 trials will soon begin in Africa. 14, 92 Vaccination of pregnant women also has the potential to reduce premature births, stillbirths, and puerperal sepsis caused by group B streptococcus. 6 
